Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

Pub.B. 1092, Pub.B. 1093, Pub.B. 1095,
Pub. B. 1096, Pub.C. 1288, Pub.C. 1289,
T h.A.4066, Th.A.4074, -Th. B.404,
Th.B.428 I,Th.B.429 I,Th.B.4300,
Th.B.4302, Th.B.4303, Th.B.4307,
Th.B.4308, Th.B.4309, Th.C.330,
Th.C.33 I,Th.C.332,Th.C.333,Th.C.334,
Th.C.335,Tu.B.2 I 46,Tu.B.23 I 9,Tu.B.2353,
Tu.B.2355,Tu.B.2357,Tu.B.2362,
Tu.B.2363,Tu.B.2364,Tu.B.2369,
Tu.[).2857, We.B. 173, We.8.300,
We.B.303, We.B.304, We.B.305,
We.B.3 I157, We.B.3247, We.B.33 18,
We.B.3352, We.B.3353, We.8.3354,
We.B.3356, We.B.3358, We.B.3360,
We.B.4 I14, We.C.3396, We.D.37 16
tumour necrosis factor (TNF)
Mo.A. 143, Mo.A.395, Mo.A.50 1,
Mo.B. 1338, Mo.8. 135 1, Mo.B. 1393,
No.B. I1394, Pub.A. I 026, Th.A. 162,
Th.A.4007, Th. B. 1 70, Th. B. I 76, Th. B.4 179,
Th. B.4300, Tu.A.2030, TL.A.2032,
Tu.B.2343,Tu.B.2386,Tu.B.2387,
We.A.307 I, We.A.3082, We.A.3084,
We.A.3086, We.A.3087, We.A.3089,
We.A.309 I, We.A.3093, We.A.3096,
We.A.3 105, We.A. 3107, We.B. 180,
We.D.3794
tumours
Mo.1266, Mo.8. 1291, No.B. 1299,
M oB. I1302, MNo. B. 1309, Pu b.B. 105 2,
Pub.B. I1062, We.B.3243, We.B.33 17
ulcers
MoB. 110, No.8.1278, MoC. 1616,
HoC. 1631, Mo.C. 1 652, Th.B.4 194,
Th.B.4277, Tu.B.22 30,Tu.B.2270,
We.B.3300
ultrasonography
Mo.B. 1272, MoB. 1273, MoB. 1274,
Tu.B.2354
ultrastructure
Mo.A. I 54, Tu.A.2009, Tu.A.2034,
We.B.3359
underreporting
NoC. 1543, Mo.C. 1545, Mo.C.202,
No.C.205, Tu.B.522
universal precautions, SEE also health
care personnel
Mo.B.I 167
urine
Th.A.4024, Th. B.4 I190, Th. B.42 37,
Th.B.4250,Th.B.4324,Tu.B.2233
urine antibodies
T h.A.4024, Tu. B.2 I167, Tu. B.2 170,
We.B.3 172
utilisation patterns
Th.C.4783,Tu.8.2 I I2,Tu.B.2 I114,
Tu.C.2594,Tu.D.276 I,u.D.2863
uveitis
Mo.8.171,Th.B.4 144, We.B.423
V3 chimeric clones
PubA. 1024
V3 loop
No.A. 1002, No.A. 1005, No.A. 1055,
No.A. 1069, No.A. 156, No.A. 163,
Mo.A.5 I 1, Pub.A. 1017, Pub.A. 1018,
Pu b. A. 1020, Th. B.4 284, Tu.A. 102,

vaccine, primate model
No.A. 103, No.A. 104, No.A.283,
No.A.400, Mo.A.404, No.A.520,
No.A.52 I, No.A.522, We.A. 142.
We.A.280, We.A.282, We.A 283,
We.A.3078, We.A.391I, We.A.393,
We.B.3372, We.8.3377
vaccine, SEE also specific vaccines
No.A. 100, No.A.280, Mo.A.520,
Mo.C.570, Pub.A. I1024.,'1 h.P. 173,
Tu.A.2098, Tu. B.40 I,'v/e. B.3371I
vaccine trials, SEE clinical trials, vaccine
No.A.280, No.A.28 I, No.A.404,
No.A.406, MoC. 1590, Mo.Ci.1593,
No.C.570,Th.8. I 77,Tu.A.273,Tu.8. 172,
Tu.C.2389,Tu.C.2536, WoJ.A.394,
We.8.293, We.B.3374, We.C.2 10,
We.C.2 12, We.C.2 14, We.C.223,
We.C.224
vaccines, subunit
No.A. 152, No.A. I153, No.A. 156,
No.A.280, No.A.28 1, No.A.283,
No.A.284, Mo.A.406, No.A.523,
MoC. I1589, Th.A. I144, Tu.A.205 I,
Tu.A.2064, Tu.A.2 101,Tu.A.2 102,
Tu.A.2 I 04,Tiu.A.2 105, We.B.3375,
We.B.3376
vaginal candidiasis (VC), SEE candidiasis
NoC. I1637, We.8.3 190, We.B.3275,
We.8.328 I, We.C.3402
vaginal fluids, transmission through
Th.C.4509, Tu.C.2685, Tu.C.443,
We.A.285, We.A.392, We.B.3368,
We.C.3580
vaginal secretion
No.A. 142, NoC. 1637, No.C.345,
Tu.C.2685, We.A.3033, We.A.390,
We.C.3506, We.C.3522
vaginal sex
Th.C.4494,Th.C.4495,Th.C.4509,
Tu.C.2400, Tu.C.2426, Tu.C.2626,
Tu.C.2692, We.C.3506
variability
No.A. 1018, No.A. 161, MoC. 1455,
HoC. 1663, Pub.A. 1010, PubA. 1020,
Th.A.4037, Th.8B.4284, Tu.A.2052,
Tu.A.205 3, Tu.A.2057, Tu.A 2063,
Tu.A.2068, Tu.A.2072, Tu.A.2075,
Tu.A.2076, Tu.A.2082, T.A.2092,
Tu.A.2093,Tu.A.284,Tu.A.37 I,Tu.A.373,
Tu.A.375,Tu.A.375,ITu.B.2239,Th.C.22 I,
We.A.3077, We.A.40 I, We.A.500,
We.8.3255, We.C.343, We.C.3464
variants, characterisation
No.A.5 I I, No.8.1 123, No.8.1 185,
Mo.C. 1470, PLub.A. 10 1 9,Th.A.4004,
Tu.A. I102, Tu.A. I105, Tu.A.2082, Tu.A.2093,
Tu.B.3 I12, We.A.404, We.B. 193,
We.8.31 IS
varicella zoster
Mo.A. I 097,Tb.A.4069,Th.B.4223,
We.8.32 14
vascular lesions
No.8.1 264, No.8. 1283, Tu.B.21I86
vertical transmission
Mo.A. 1100, No.8.1304, No.8.1325,
No.C. 1404, NoC. 1493, No.C. 1562,

Th.C.4 I 5,Th.C.4822, Tu.C.2570,
Tu. C. 2579,Tu.C.2605, We.C.3580,

We.C.3583
vertical transmission, chemoprophylaxis
No.8. 11I30, Th.C.4822, Tu.B.2252,
Tu.C.2574, Tu.C.2595, Tu.C.2598,
Tu.C.440,Tu.C.44 I,Tu.C.442,Tu.C.444,
We.C.3588, We.C.3590
vertical transmission, diagnosis
No.8. 1 I75,Th.B.4327,Tu.C.2596,
Tu.C.2602, We.A.30 I12,We.B.3 176,
We.B.3328, We.C.3436
vertical transmission, mode of delivery
MNo. B.54 3,Th.B. 4 I87, Tu.B.2277,
Tu.C.2570,Tu.C.2579,Tu.C.2602,
Tu.C.2603, Tu.C.340, Tu.C.342, Tu.C.343,
Tu.C.442, We.C.330
vertical transmission, predictors
Th.B.4322,Tu.C.2578,Tu.C.2579,
Tu.C.2583,Tu.C.2589,Tu.C.259 1,
Tu.C.2599,Tu.C.2600,Tu.C.340,Tu.C.34 I,
Tu.C,343, Tu.C.344,Tu.C.440,Tu.C.442
vertical transmission, premature
rupture
Tu.C.2603,Tu.C.440
vertical transmission, prevention of
No.8. 11 3 0, o.C.21 I,Pub.C.I1181,
Th.B.4 I187, Th.C.4 I I, Th.C.4 I13, Th.C.4 IS,
Th.C.4592, Eh.C.46 I 5,Th.C.4772,
Th.C.4807, Th.C.48 I17, Th.C.4822,
Th.D.5022,Tu.C.257 I,Tu.C.2575,
Tu.C.2578,Tu.C.2580,Tu.C.2586,
Tu.C.2590,Tii.C.2594,Tu.C.2595,
Tu.C.2602,Tj.C.2603,Tu.C.342,Tu.C.44 I,
Tu.C.442, Tu.C.444, Tu.D.2728, Tu.D.2772,
We.B.3 I163, We.C.3399, We.C.3580,
We.C.3583, We.C.3584, We.C.3587,
We.C.3588, We.C.3589, We.C.3590,
We.C.3592, We.C.3593, We.C.3599,
We.D.3838
vertical transmission, risk of
Pub.C. 11I37, Th.B.4322, Th.B.4326,
Tu.C.2570,Tu.C.2579,Tu.C.2580,
Tu.C.2583,Tu.C.2592,Tu.C.2599,
Tu.C.2600,Tu.C.2603,Tu.C.34 I,Tu.C.343,
Tu.C.345, u.C.440,Tu.C.44 I, We.B. 193
Vif gene
No.A. 1027, No.A. 1036
vif protein
No.A. 1027, No.A. 1036
viral infections
No.A. 1007, No.A.403, No.8.1240,
No.8.1246, No.8. I128 1, Pub.A. 1029,
Th.A.273,Th.B.305,Th.B.4274,Tu.B. 184,
Tu.B. I85,Tu.B.2 I 54,Tu.B.2 I 84,Tu.B.2 I185,
Tu.B.2204,Tu.C.25 17, We.B.32 I13
viral interference
No.A, 1021, No.A. 1042, No.A. 1070,
Th.A. 150, Th.B.4 I107, Tu.A.203 7,Tlu.A.393,
Tu.B.22OS, We.A.274
viral latency
Mo.A. 1025, No.A.502, Tu.A. 142,
We.C.3466
viral load
No.A. 1080, No.A. 1083, No.A. 1096,
Mo.A.I 1 05, Mo.A. I I I l,No.A.I113,
No.A. 160, No.A. 161, No.A.390,
No.A.393, No.A.400, No.8. 1120,
No.8. 1122, No.8. 1128, No.B. 11I32,

1.8.4336,Th.8.4337,Th.B.4339,
Th.8.4340, Ih.8.434 I,Th.B.4343,

Th.B.4352,Tu.A. I 52,Tu.A. I 55,Tu.A. I161,
Tu.A.20 I13, fu.A.2088, Th.A.262, Tu.A.263,
Tu.A.385, Tu.B. I 93, Tu.B.2 I123, Tu.B.2238,
Tu.B.2243,Tu.8.2244,Tu.8.2267,
Tu.B.2332,Tu.B.2370, Tu.8.237 I,
Tu.B.2372, Tu.B.2375, Tu.C.2522,
Tu.C.2578,Tu.C.2580,Tu.C.2583,
Tu.C.2587, Tu.C.2597, Tu.C.343, Tu.C.344,
Tu.C.443,Tu.C.552,Tu.C.553, We.A.3024,
We.A.3067, We.A.400, We.A.402,
We.A.404, We.A.520, We.A.52 I,
We.A.522, We.A.523, We.B. I I I,
We. B.l113, We.8B.l114, We.B. 191,
We.B.291, We.B.31 I, We.B.31 19,
We.B.3 I120, We.B.3 12 I, We.B.3 128,
We.B.3 I134, We.B.3 I140, We.B.3 IS,
We.B.3 I168, We.B.3 I194, We.B.3 198,
We.B.3327, We.B.3380, We.B.3382,
We.B.4 10, We.B.4 I I, We.B.4 14,
We.B.533, We.C.332, We.C.3399,
We.C.3422, We.C.3450, We.C.3459,
WeC.3464, We.C.3467, We.C.3472
viral morphology
No.A. 154, HoC. 1443
viral proteins
No.A. 1032, No.A. 1037, No.A. 1047,
Th.A.382,Th.A.385, We.A.3062
viral replication
No.A. 1021, No.A. 1043, No.A. 1047,
No.A. 1063, Mo.A. 1 100, No.A.383,
MoASO I, No.A.502, No.8.1258,
Pub.A. 1015, Pub.A. 10 1 6,Th.A. 103,
Th.A. I 45, Th.A.380, Th.A.4060,
Th.B.4 I198, Th.B.4329, Th.B.4343,
Th.B.435 I,Tu.A. I14 I,Tu.A. 143, Tu.A. I1SS,
Tu.A.5 I, Tu.A.503, Tu.A.S I10, Tu.B.2282,
Tu.B.40 I, Tu.C.2685, We.A.3090,
We.A.402, We.A.500, We.B. I I I,
We.B. II4, We.C.3466
viremia
No.8.1236, No.8.1241, No.8. 1332,
No.8. 1348, No.8. 1376, No.8. 175,
Th.8B.4 33 9,Tu.A.2060, Tu.A.2 108,
Tu.B.2 I1I5, TL.B.2208, Tu.B.2223,
Tu.B.2349, We.A.3005, We.C.3398
virulence
Tu.A.2080
virus burden, SEE viral load
No.8.1 139, No.8. 1337, No.B. 1348,
Th.B.4 11I8, Th.8.4339,Th.8.4352,
Tu.8.2243,Tu.8.2349, We.A.520,
We.B.3287, We.B.338 I, We.B.3385
visual deficits
No.8. 1195, No.B.1221, Tu.8.2 185
vitamins
No.8. 1315, No.8. 1317, No.C.320,
Th. B.4095, Th. B.4237, Th. B.4250,
Tu.A.203 I,TL.B.225 I,Tu.8.2275,
Tu.C.2598, We.B. I185, We.B.3257,
We.B.3258, We.B.3259, We.B.326 I,
We.B.3264, We.B.326 7, We.B.3268,
We.B.3270
voluntary testing, SEE testing, voluntary
Ho.C. 1553, Pub.D. I13 10, Pub.D. 1.496,
Th.C.4725,Tu.C.2624, We.D.388 6
volunteers
No.B. 1149, NoB.IISO, No.8.30S,

warts
No.8. 1244,Ju.D.2779

\O
O\
0
u
c
0
c
0
a)
a)
0
U
c
0
C
a)

502